News
UTHR
482.26
+1.43%
6.81
Weekly Report: what happened at UTHR last week (0921-0925)?
Weekly Report · 6h ago
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
Seeking Alpha · 1d ago
Sell Rating Could Reshape The Case For United Therapeutics Stock (UTHR)
Simply Wall St · 1d ago
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 2d ago
United Therapeutics (UTHR) Faces Yutrepia Pressure, Is It Still 29% Undervalued?
Simply Wall St · 3d ago
United Therapeutics Downgraded to Sell as Premium Valuation Clashes with Shrinking Core Business and Challenging Launch Outlook for Tyvaso and Jenraldi
TipRanks · 3d ago
Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating
NASDAQ · 3d ago
Why United Therapeutics (UTHR) Shares Are Falling Today
Barchart · 4d ago
United Therapeutics Price Target Announced at $321.00/Share by Goldman Sachs
Dow Jones · 4d ago
CoreWeave upgraded, Etsy downgraded: Wall Street’s top analyst calls
TipRanks · 4d ago
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321
Benzinga · 4d ago
United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings
Seeking Alpha · 4d ago
United Therapeutics initiated with a Sell at Goldman Sachs
TipRanks · 4d ago
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
Seeking Alpha · 4d ago
SPMD, THC, UTHR, XPO: ETF Inflow Alert
NASDAQ · 09/21 14:55
Weekly Report: what happened at UTHR last week (0914-0918)?
Weekly Report · 09/21 09:25
United Therapeutics (UTHR) Pullback Keeps Its Pipeline Led Valuation Story In Focus
Simply Wall St · 09/17 19:20
Does FDA Filing Acceptance Change The Bull Case For United Therapeutics Stock?
Simply Wall St · 09/14 11:29
Weekly Report: what happened at UTHR last week (0907-0911)?
Weekly Report · 09/14 09:26
Is United Therapeutics (UTHR) Still A Bargain, Or Largely Priced In?
Simply Wall St · 09/12 07:22
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.